Articles by Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jim Miller
123456789101112
Next »

Strategic Partnering for Manufacturing

Eisai and Biogen Idec pursue an innovative approach to capacity management.
May 3, 2013
By: Jim Miller

Eisai and Biogen Idec pursue an innovative approach to capacity management.

Strategic Partnering for Manufacturing

Eisai and Biogen Idec pursue an innovative approach to capacity management.
Apr 2, 2013
By: Jim Miller

Eisai and Biogen Idec pursue an innovative approach to capacity management.

End of the Dedicated CMO?

Is the contract-only CMO an endangered species?
Mar 6, 2013
By: Jim Miller

Is the contract-only CMO an endangered species?

End of the Dedicated CMO?

Is the contract-only CMO an endangered species?
Feb 2, 2013
By: Jim Miller

Is the contract-only CMO an endangered species?

The State of Outsourcing Partnerships

Preferred-provider relationships are transforming the bio/pharmaceutical industry.
Feb 1, 2013
By: Jim Miller

Preferred-provider relationships are transforming the bio/pharmaceutical industry.

Acquisitions Reshape the Bio/Pharm Services Industry

The quest to build critical mass and broaden capabilities has been a key factor in dealmaking.
Jan 9, 2013
By: Jim Miller

The quest to build critical mass and broaden capabilities has been a key factor in dealmaking.

Acquisitions Reshape the Bio/Pharm Services Industry

The quest to build critical mass and broaden capabilities has been a key factor in deal-making.
Dec 2, 2012
By: Jim Miller

The quest to build critical mass and broaden capabilities has been a key factor in deal-making.

Sizing the Market For Contract Manufacturing

Measuring the size of the market for contract manufacturing services requires a careful hand.
Nov 7, 2012
By: Jim Miller

Measuring the size of the market for contract manufacturing services requires a careful hand.

The Macro View

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.
Oct 3, 2012
By: Jim Miller

The weak global economy adds to the challenges of bio/pharma companies and their suppliers.

123456789101112
Next »

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here